Literature DB >> 28117886

Hepatitis C virus infection and the risk of cancer among elderly US adults: A registry-based case-control study.

Parag Mahale1,2, Harrys A Torres3, Jennifer R Kramer4, Lu-Yu Hwang2, Ruosha Li5, Eric L Brown2, Eric A Engels1.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection causes hepatocellular carcinoma (HCC) and subtypes of non-Hodgkin lymphoma (NHL). Associations with other cancers are not established. The authors systematically assessed associations between HCV infection and cancers in the US elderly population.
METHODS: This was a registry-based case-control study using Surveillance, Epidemiology, and End Results (SEER)-Medicare data in US adults aged ≥66 years. Cases (n = 1,623,538) were patients who had first cancers identified in SEER registries (1993-2011). Controls (n = 200,000) were randomly selected, cancer-free individuals who were frequency-matched to cases on age, sex, race, and calendar year. Associations with HCV (documented by Medicare claims) were determined using logistic regression.
RESULTS: HCV prevalence was higher in cases than in controls (0.7% vs 0.5%). HCV was positively associated with cancers of the liver (adjusted odds ratio [aOR] = 31.5; 95% confidence interval [CI], 29.0-34.3), intrahepatic bile duct (aOR, 3.40; 95% CI, 2.52-4.58), extrahepatic bile duct (aOR, 1.90; 95% CI, 1.41-2.57), pancreas (aOR, 1.23; 95% CI, 1.09-1.40), and anus (aOR, 1.97; 95% CI, 1.42-2.73); nonmelanoma nonepithelial skin cancer (aOR, 1.53; 95% CI, 1.15-2.04); myelodysplastic syndrome (aOR, 1.56; 95% CI, 1.33-1.83); and diffuse large B-cell lymphoma (aOR, 1.57; 95% CI, 1.34-1.84). Specific skin cancers associated with HCV were Merkel cell carcinoma (aOR, 1.92; 95% CI, 1.30-2.85) and appendageal skin cancers (aOR, 2.02; 95% CI, 1.29-3.16). Inverse associations were observed with uterine cancer (aOR, 0.64; 95% CI, 0.51-0.80) and prostate cancer (aOR, 0.73; 95% CI, 0.66-0.82). Associations were maintained in sensitivity analyses conducted among individuals without documented alcohol abuse, cirrhosis, or hepatitis B or human immunodeficiency virus infections and after adjustment for socioeconomic status. Associations of HCV with other cancers were not observed.
CONCLUSIONS: HCV is associated with increased risk of cancers other than HCC in the US elderly population, notably bile duct cancers and diffuse large B-cell lymphoma. These results support a possible etiologic role for HCV in an expanded group of cancers. Cancer 2017;123:1202-1211.
© 2016 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  Epidemiology; Surveillance; and End Results (SEER)-Medicare; cancers; cholangiocarcinoma; elderly; hepatitis C virus; hepatocellular carcinoma; lymphoma

Mesh:

Year:  2017        PMID: 28117886      PMCID: PMC6295146          DOI: 10.1002/cncr.30559

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  45 in total

1.  Risk of thyroid cancer and high prevalence of hepatitis C virus.

Authors:  Maurizio Montella; Luciano Pezzullo; Anna Crispo; Francesco Izzo; Alfonso Amore; Ugo Marone; Mario Tamburini; Domenico Ronga; Maria Grazia Chiofalo; Gennaro Chiappetta; Nicola Mozzillo
Journal:  Oncol Rep       Date:  2003 Jan-Feb       Impact factor: 3.906

2.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

3.  Detection of HCV in bile duct epithelium by laser capture microdissection (LCM).

Authors:  E A Fillipowicz; S y Xiao; L E Sower; J Weems; D A Payne
Journal:  In Vivo       Date:  2005 Jul-Aug       Impact factor: 2.155

4.  Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States.

Authors:  Vivekanandan Perumal; Jianzhou Wang; Paul Thuluvath; Michael Choti; Michael Torbenson
Journal:  Hum Pathol       Date:  2006-07-18       Impact factor: 3.466

5.  Effect of hepatitis C virus core protein on modulation of cellular proliferation and apoptosis in hilar cholangiocarcinoma.

Authors:  Ru-Fu Chen; Zhi-Hua Li; Sheng-Quan Zou; Ji-Sheng Chen
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2005-02

6.  Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C.

Authors:  Fu-Ming Yan; An-Shen Chen; Fei Hao; Xi-Ping Zhao; Chang-Hai Gu; Li-Bin Zhao; Dong-Liang Yang; Lian-Jie Hao
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 7.  Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome.

Authors:  H J Alter; L B Seeff
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

8.  Changing relationship between socioeconomic status and prostate cancer incidence.

Authors:  L Liu; W Cozen; L Bernstein; R K Ross; D Deapen
Journal:  J Natl Cancer Inst       Date:  2001-05-02       Impact factor: 13.506

9.  Molecular evidence that the hepatitis C virus replicates in the oral mucosa.

Authors:  Marco Carrozzo; Rafael Quadri; Patrizia Latorre; Monica Pentenero; Simona Paganin; Giorgio Bertolusso; Sergio Gandolfo; Francesco Negro
Journal:  J Hepatol       Date:  2002-09       Impact factor: 25.083

10.  Extrahepatic manifestations of hepatitis C among United States male veterans.

Authors:  Hashem B El-Serag; Howard Hampel; Christine Yeh; Linda Rabeneck
Journal:  Hepatology       Date:  2002-12       Impact factor: 17.425

View more
  24 in total

Review 1.  Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology).

Authors:  Aysegul Ozakyol
Journal:  J Gastrointest Cancer       Date:  2017-09

2.  Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer.

Authors:  Minas P Economides; Moran Amit; Parag S Mahale; Jeff J Hosry; Ying Jiang; Uddalak Bharadwaj; Erich M Sturgis; Harrys A Torres
Journal:  Cancer       Date:  2017-11-17       Impact factor: 6.860

Review 3.  Epidemiological and etiological variations in hepatocellular carcinoma.

Authors:  Evangelista Sagnelli; Margherita Macera; Antonio Russo; Nicola Coppola; Caterina Sagnelli
Journal:  Infection       Date:  2019-07-25       Impact factor: 3.553

Review 4.  The oncologic burden of hepatitis C virus infection: A clinical perspective.

Authors:  Harrys A Torres; Terri Lynn Shigle; Nassim Hammoudi; James T Link; Felipe Samaniego; Ahmed Kaseb; Vincent Mallet
Journal:  CA Cancer J Clin       Date:  2017-07-06       Impact factor: 508.702

Review 5.  Association between viral infection other than human papillomavirus and risk of esophageal carcinoma: a comprehensive meta-analysis of epidemiological studies.

Authors:  Hui Geng; Yaqi Xing; Jingbing Zhang; Kexin Cao; Meijie Ye; Geng Wang; Caixia Liu
Journal:  Arch Virol       Date:  2021-10-12       Impact factor: 2.574

6.  Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US.

Authors:  Wei Wang; Vincent Lo Re; Yi Guo; Hong Xiao; Joshua Brown; Haesuk Park
Journal:  Aliment Pharmacol Ther       Date:  2020-09-15       Impact factor: 8.171

Review 7.  Hepatitis C Virus Infection in the Older Patient.

Authors:  Michael Reid; Jennifer C Price; Phyllis C Tien
Journal:  Infect Dis Clin North Am       Date:  2017-12       Impact factor: 5.982

Review 8.  Extrahepatic cancers and chronic HCV infection.

Authors:  Stanislas Pol; Anaïs Vallet-Pichard; Olivier Hermine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-17       Impact factor: 46.802

9.  Higher Levels of Fibrosis in a Cohort of Veterans with Chronic Viral Hepatitis are Associated with Extrahepatic Cancers.

Authors:  Ameer Abutaleb; Jose Antonio Almario; Saleh Alghsoon; Ji Ae Yoon; Kate Gheysens; Shyam Kottilil; Eleanor Wilson
Journal:  J Clin Exp Hepatol       Date:  2020-08-09

Review 10.  Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications.

Authors:  Nguyen H Tran
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.